

RECORDATI: PUBLICATION OF DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS CALLED FOR 29.04.2025

Milan, 28th March 2025 – Please be informed that the **2024 Annual Financial Report** (including the Separate Financial Statements and the Consolidated Financial Statements as at 31st December 2024, together with the related Directors' Report on Operations, including the Consolidated Sustainability Statement, and the required Certifications), coupled with the **Reports issued by the Auditing Firm**, as well as the **Report issued by the Board of Statutory Auditors**, are available to the public, as of today, at the Company's registered office and published on the Company's website (www.recordati.com - Investors – Shareholder Information section) and on the '1INFO' storage mechanism (www.1info.it).

In addition, please be informed that the following reports approved by the Board of Directors of Recordati S.p.A. on 18th March 2025:

- (i) the **2024 Corporate Governance Report and Ownership Structure**; and
- (ii) the **Directors' Report relating to item no. 1 (Financial statements approval and allocation of profit)** of the agenda of the Ordinary Shareholders' Meeting called for 29th April 2025,

are also available to the public, as of today, at the Company's registered office and published on the Company's website (www.recordati.com, the first report in the Governance – Corporate Governance Report section; and the second report in the Investors - Shareholder Information section) and on the '1INFO' storage mechanism (www.1info.it).

***Recordati** is an international pharmaceutical group listed on the Italian Stock Exchange (XMIL: REC), with roots dating back to a family-run pharmacy in Northern Italy in the 1920s. We are uniquely structured to provide treatments across specialty and primary care, and rare diseases. Our fully integrated operations span clinical development, chemical and finished product manufacturing, commercialization and licensing. We operate in approximately 150 countries across EMEA, the Americas and APAC with over 4,450 employees. We believe that health is a fundamental right, not a privilege. Today, our purpose of "unlocking the full potential of life" aims at empowering individuals to live life to the fullest, whether addressing common health challenges or the rarest.*

Investor Relations

Eugenia Litz
+44 7824 394 750
investorelations@recordati.it

Gianluca Saletta
+39 348 979 4876
investorelations@recordati.it

Media Relations

ICR Healthcare US:
Alexis Feinberg
[+1 203 939 2225](tel:+12039392225)
recordatiuspr@westwicke.com

UK, Europe & Rest of World:
Jessica Hodgson
+44 7561 424 788
recordati@consilium-comms.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office
Via Matteo Civitali, 1
20148 Milano, Italy
Tel. +39 02 487871
Fax +39 02 40073747
www.recordati.com

Share Capital € 26.140.644,50 fully paid-up
Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150
Tax Code/VAT No. 00748210150
Milano R.E.A. No. 401832